My bookmarksSign up free
Source

Commission Delegated Regulation (EU) 2017/2100 of 4 September 2017 setting out scientific criteria for the determination of endocrine-disrupting properties pursuant to Regulation (EU) No 528/2012 of the European Parliament and Council (Text with EEA relevance. )

Commission Delegated Regulation (EU) 2017/2100 of 4 September 2017 setting out scientific criteria for the determination of endocrine-disrupting properties pursuant to Regulation (EU) No 528/2012 of the European Parliament and Council (Text with EEA relevance. )

Delegated Regulation (EU) 2017/2100 · Regulation · 5 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

Open ↗

The scientific criteria for the determination of endocrine-disrupting properties pursuant to Regulation (EU) No 528/2012 are set out in the Annex to this Regulation.

Article 2

Open ↗

The criteria laid down in the Annex to this Regulation shall apply as of 7 June 2018, except for procedures where the Committee referred to in Article 82 of Regulation (EU) No 528/2012 has voted on a draft Regulation by 7 June 2018.

Article 3

Open ↗

By 7 June 2025, the Commission shall present to the expert group (the ‘Biocides CA meeting’) consisting of representatives of Member States' competent authorities for biocidal products an assessment of the experience gained from the application of the scientific criteria for the determination of endocrine-disrupting properties introduced by the present Regulation.

Article 4

Open ↗

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union . It shall apply from 7 June 2018.

Supplementary provisions

ANNEXSupplementary provisions

Open ↗

ANNEX A substance shall be considered as having endocrine-disrupting properties with respect to humans or non-target organisms, where it meets the criteria set out in section A or section B. Section A — Endocrine-disrupting properties with respect to humans (1) A substance shall be considered as having endocrine-disrupting properties that may cause adverse effect in humans if, based on points (a) to (d) of point (2), it is a substance that meets all of the following criteria, unless there is evidence demonstrating that the adverse effects identified are not relevant to humans: (a) it shows an adverse effect in an intact organism or its progeny, which is a change in the morphology, physiology, growth, development, reproduction or life span of an organism, system or (sub)population that results in an impairment of functional capacity, an impairment of the capacity to compensate for additional stress or an increase in susceptibility to other influences; (b) it has an endocrine mode of action, i.e. it alters the function(s) of the endocrine system; (c) the adverse effect is a consequence of the endocrine mode of action. (2) The identification of a substance as having endocrine-disrupting properties that may cause adverse effect in humans in accordance with point (1) shall be based on all of the following points: (a) all available relevant scientific data ( in vivo studies or adequately validated alternative test systems predictive of adverse effects in humans or animals; as well as in vivo , in vitro , or, if applicable, in silico studies informing about endocrine modes of action): (i) scientific data generated in accordance with internationally agreed study protocols, in particular those referred to in Annexes II and III of Regulation (EU) No 528/2012; (ii) other scientific data selected applying a systematic review methodology; (b) an assessment of the available relevant scientific data based on a weight of evidence approach in order to establish whether the criteria set out in point (1) are fulfilled; in applying the weight of evidence determination, the assessment of the scientific evidence shall, in particular, consider all of the following factors: (i) both positive and negative results; (ii) the relevance of the study designs for the assessment of adverse effects and of the endocrine mode of action; (iii) the quality and consistency of the data, considering the pattern and coherence of the results within and between studies of a similar design and across different species; (iv) the route of exposure, toxicokinetic and metabolism studies; (v) the concept of the limit dose, and international guidelines on maximum recommended doses and for assessing confounding effects of excessive toxicity; (c) using a weight of evidence approach, the link between the adverse effect(s) and the endocrine mode of action shall be established based on biological plausibility, which shall be determined in the light of current scientific knowledge and under consideration of internationally agreed guidelines; (d) adverse effects that are non-specific secondary consequences of other toxic effects shall not be considered for the identification of the substance as endocrine disruptor. Section B — Endocrine-disrupting properties with respect to non-target organisms (1) A substance shall be considered as having endocrine-disrupting properties that may cause adverse effects on non-target organisms if, based on points (a) to (d) of point (2), it is a substance that meets all of following criteria, unless there is evidence demonstrating that the adverse effects identified are not relevant at the (sub)population level for non-target organisms: (a) it shows an adverse effect in non-target organisms, which is a change in the morphology, physiology, growth, development, reproduction or life span of an organism, system or (sub)population that results in an impairment of functional capacity, an impairment of the capacity to compensate for additional stress or an increase in susceptibility to other influences; (b) it has an endocrine mode of action, i.e. it alters the function(s) of the endocrine system; (c) the adverse effect is a consequence of the endocrine mode of action. (2) The identification of a substance as having endocrine-disrupting properties that may cause adverse effects on non-target organisms in accordance with point (1) shall be based on all of the following points: (a) all available relevant scientific data ( in vivo studies or adequately validated alternative test systems predictive of adverse effects in humans or animals; as well as in vivo , in vitro or, if applicable, in silico studies informing about endocrine modes of action): (i) scientific data generated in accordance with internationally agreed study protocols, in particular those referred to in Annexes II and III of Regulation (EU) No 528/2012; (ii) other scientific data selected applying a systematic review methodology; (b) an assessment of the available relevant scientific data based on a weight of evidence approach in order to establish whether the criteria set out in point 1 are fulfilled; in applying the weight of evidence determination, the assessment of the scientific evidence shall consider all of the following factors: (i) both positive and negative results, discriminating between taxonomic groups (e.g. mammals, birds, fish, amphibians) where relevant; (ii) the relevance of the study design for the assessment of the adverse effects and its relevance at the (sub)population level, and for the assessment of the endocrine mode of action; (iii) the adverse effects on reproduction, growth/development, and other relevant adverse effects which are likely to impact on (sub)populations. Adequate, reliable and representative field or monitoring data and/or results from population models shall as well be considered where available; (iv) the quality and consistency of the data, considering the pattern and coherence of the results within and between studies of a similar design and across different taxonomic groups; (v) the concept of the limit dose and international guidelines on maximum recommended doses and for assessing confounding effects of excessive toxicity; (c) using a weight of evidence approach, the link between the adverse effect(s) and the endocrine mode of action shall be established based on biological plausibility, which shall be determined in the light of current scientific knowledge and under consideration of internationally agreed guidelines; (d) adverse effects that are non-specific secondary consequences of other toxic effects shall not be considered for the identification of the substance as endocrine disruptor with respect to non-target organisms. (3) If the intended biocidal mode of action of the active substance being assessed consists of controlling target organisms other than vertebrates via their endocrine systems, the effects on organisms of the same taxonomic phylum as the targeted one shall not be considered for the identification of the substance as having endocrine-disrupting properties with respect to non-target organisms.

Other acts of the same type
Commission Delegated Regulation (EU) 2018/273 of 11 December 2017 supplementing Regulation (EU) No 1308/2013 of the European Parliament and of the Council as regards the scheme of authorisations for vine plantings, the vineyard register, accompanying documents and certification, the inward and outward register, compulsory declarations, notifications and publication of notified information, and supplementing Regulation (EU) No 1306/2013 of the European Parliament and of the Council as regards the relevant checks and penalties, amending Commission Regulations (EC) No 555/2008, (EC) No 606/2009 and (EC) No 607/2009 and repealing Commission Regulation (EC) No 436/2009 and Commission Delegated Regulation (EU) 2015/560Commission Implementing Regulation (EU) 2018/274 of 11 December 2017 laying down rules for the application of Regulation (EU) No 1308/2013 of the European Parliament and of the Council as regards the scheme of authorisations for vine plantings, certification, the inward and outward register, compulsory declarations and notifications, and of Regulation (EU) No 1306/2013 of the European Parliament and of the Council as regards the relevant checks, and repealing Commission Implementing Regulation (EU) 2015/561Commission Implementing Regulation (EU) 2017/2272 of 8 December 2017 entering a name in the register of traditional specialities guaranteed (‘Kabanosy staropolskie’ (TSG))Commission Implementing Regulation (EU) 2017/2274 of 8 December 2017 concerning the authorisation of a new use of a preparation of 6-phytase (EC 3.1.3.26) produced by Komagataella pastoris (DSM 23036) as a feed additive for fish (holder of authorisation Huvepharma EOOD) (Text with EEA relevance. )Commission Implementing Regulation (EU) 2017/2275 of 8 December 2017 concerning the authorisation of a new use of the preparation of Lactobacillus acidophilus (CECT 4529) as a feed additive for chickens for fattening (holder of the authorisation Centro Sperimentale del Latte) (Text with EEA relevance. )Commission Implementing Regulation (EU) 2017/2241 of 6 December 2017 on the extension of the transitional periods related to own funds requirements for exposures to central counterparties set out in Regulations (EU) No 575/2013 and (EU) No 648/2012 of the European Parliament and of the Council (Text with EEA relevance. )Commission Implementing Regulation (EU) 2017/2363 of 6 December 2017 entering a name in the register of protected designations of origin and protected geographical indications (‘Μελεκούνι’ (Melekouni) (PGI))Commission Implementing Regulation (EU) 2017/2236 of 5 December 2017 amending Regulation (EC) No 3199/93 on the mutual recognition of procedures for the complete denaturing of alcohol for the purposes of exemption from excise dutyCommission Implementing Regulation (EU) 2017/2260 of 5 December 2017 amending Council Regulation (EU) 2016/44 concerning restrictive measures in view of the situation in LibyaCommission Implementing Regulation (EU) 2017/2362 of 5 December 2017 entering a name in the register of protected designations of origin and protected geographical indications (‘Lenticchia di Altamura’ (PGI))Council Regulation (EU) 2017/2454 of 5 December 2017 amending Regulation (EU) No 904/2010 on administrative cooperation and combating fraud in the field of value added taxCouncil Implementing Regulation (EU) 2017/2459 of 5 December 2017 amending Implementing Regulation (EU) No 282/2011 laying down implementing measures for Directive 2006/112/EC on the common system of value added tax

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

Contents

What to look at next